(Q45360379)

13 December 2017

title

Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance (English)

1 reference

13 December 2017

0 references

1 reference

Stéphane Chevaliez

1

1 reference

13 December 2017

publication date

1 December 2011

1 reference

Clinics and research in hepatology and gastroenterology

13 December 2017

published in

1 reference

13 December 2017

volume

35 Suppl 2

1 reference

13 December 2017

page(s)

S46-51

1 reference

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Therapeutic implications of hepatitis C virus resistance to antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Hepatitis C virus population dynamics during infection.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

A perspective on modelling hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Rates of evolutionary change in viruses: patterns and determinants

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Sequencing technologies - the next generation

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2811%2970007-9

7 January 2021

10.1016/S2210-7401(11)70007-9

Identifiers

DOI

1 reference

13 December 2017

1 reference